Clinical Trial Update: A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients [Phase 2, Phase 3]

View source ↗

Summary

A long-term extension study of SPM 962 in early Parkinson's disease patients has completed Phase II/III. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SPM 962

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Parkinson's Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-03-19